SOURCE: The Bedford Report

The Bedford Report

May 02, 2011 08:16 ET

Stem Cell Stocks on the Upswing as Outlook Brightens

The Bedford Report Provides Analyst Research on Geron & StemCells

NEW YORK, NY--(Marketwire - May 2, 2011) - There is plenty of optimism surrounding the biotech sector as firmer pricing and new products have improved sales and earnings trends. Meanwhile, younger, more speculative firms continue to garner significant attention with potential blockbuster products working their way through the regulatory process. The Bedford Report examines the outlook for companies in the Biotechnology Industry and provides research reports on Geron Corporation (NASDAQ: GERN) and StemCells, Inc. (NASDAQ: STEM). Access to the full company reports can be found at:

IMS Health, a leading research and analytical firm serving the pharmaceutical and medical industries, projects an increase in worldwide biotech growth in 2011 of between 5 and 7 percent, with a similar outlook stretching out to 2015. Emerging markets such as China, India, and Brazil are expected to contribute significantly to this growth. Sales growth of 15 percent is forecast in emerging markets, many of which are benefitting from increased government spending on healthcare and broader private health coverage for workers.

The Bedford Report releases regular market updates on the Healthcare Sector so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us free at and get exclusive access to our numerous analyst reports and industry newsletters.

Stem cell stocks got a nice bump on Friday after a federal court gave the Obama administration the go-ahead to continue funding embryonic stem cell research. Researchers hope to use stem cells in ways that cure spinal cord injuries, Parkinson's disease and other ailments. Opponents say the research is a form of abortion because human embryos must be destroyed to obtain the stem cells.

Currently Geron and Advanced Cell Technologies are the only two US companies in advanced stages of testing human embryonic stem cells. StemCells, Inc., meanwhile, is studying tissue-derived stem cells for its therapeutic approach and doesn't even use embryonic stem cells.

The Bedford Report provides Analyst Research focused on equities that offer growth opportunities, value, and strong potential return. We strive to provide the most up-to-date market activities. We constantly create research reports and newsletters for our members. The Bedford Report has not been compensated by any of the above-mentioned publicly traded companies. The Bedford Report is compensated by other third party organizations for advertising services. We act as an independent research portal and are aware that all investment entails inherent risks. Please view the full disclaimer at

Contact Information